The Food and Drug Administration today is alerting health care professionals and patients about early results of new studies for Paxil (paroxetine) suggesting that the drug increases the risk for birth defects, particularly heart defects, when women take it during the first three months of pregnancy. Paxil is approved for the treatment of depression and several other psychiatric disorders. FDA is currently gathering additional data and waiting for the final results of the recent studies in order to better understand the higher risk for birth defects that has been seen with Paxil.
Dec. 8 - FDA Advising of Risk of Birth Defects with Paxil
Thursday, December 8, 2005
I found the people at Nexreg very helpful when it came to addressing my Canadian product labelling needs. They were always readily available to answer questions and concerns. I'm very glad to have the Nexreg people in my corner when dealing with Canadian compliancy regulations.
Rick McVicar, 2nd Wind Distributors